Table 1.

Clinical characteristics of study population.

Discovery Set (N=29)
	Age Range (Median)	Gender	non-PDAC pathology	TNM stage	Clinical Stage
Healthy Controls	62.0–69.4 (64.7)	n=4 Male n=3 Female
Disease Control	43.4–72.0 (70.7)	n=4 Male n=1 Female	n=4 Pancreatitis n=1 Billary Stricture
M0	60.5–71.5 (68.3)	n=3 Male n=1 Female		n=2 cT2cN0M0 n=1 cT3cN0M0 n=1 cTxN0M0	n=2 IB n=1 IIA n=1 X
M1	51.0–67.0 (64.0)	n=7 Male n=6 Female		n=4 cT3N1M1 n=1 cT4N1M1 n=8 cTxNxM1	n=13 IV
Training Set (N=47)
	Age Range (Median)	Gender	non-PDAC pathology	TNM stage	Clinical Stage
Healthy Controls	45.6–75.3 (62.3)	n=8 Male n=7 Female
Disease Control	43.4–82.2 (65.0)	n=10 Male n=2 Female	n=9 Pancreatitis n=3 IPMN
M0	54.4–77.7 (65.2)	n=3 Male n=6 Female		n=3 cT1cN0M0 n=1 cT1cNxM0 n=5 cT2N0M0	n=3 IA n=5 IB n=1 X
M1	51.0–81.5 (67.5)	n=5 Male n=6 Female		n=1 cT1cN0M1 n=2 cT2N0M1 n=1 cT2N1M1 n=1 cT2N0M1 n=1 cT3N1M1 n=2 cT4N1M1 n=1 cTxN0M1 n=2 cTxN1M1	n=11 IV
Test Set (N=136)
	Age Range (Median)	Gender	non-PDAC pathology	TNM stage	Clinical Stage
Healthy Controls	41.6–85.8 (66.0)	n=20 Male n=29 Female
Disease Control	19.9–83.1 (63.7)	n=13 Male n=17 Female	n=3 IPMN n=12 Pancreatitis n=2 Biliary Stricture n=1 Benign Neurofibroma n=11 Pancreatic Cyst n=1 Pancreatic Duct Dilation
M0	50.5–85.4 (66.5)	n=26 Male n=19 Female		n=3 cT1cN0M0 n=16 cT2N0M0 n=4 cT2N1M0 n=7 cT3N0M0 n=4 cT3N1M0 n=3 cT4N0M0 n=1 cT4N0M1 n=5 cT4N1M0 n=2 cT4N1M1	n=3 IA n=15 IB n=7 IIA n=9 IIB n=8 III n=3 IV
M1	48.6–71.2 (62.5)	n=7 Male n=5 Female		n=1 cT0N0M1 n=1 cT2N0M1 n=1 cT2N1M1 n=2 cT3N0M1 n=1 cT3NxM1 n=2 cT4N0M1 n=4 cT4N1M1	n=12 IV

^*indicates 8 patients are included in the discovery as well as training sets. Designation of M0 versus M1 is based on baseline imaging.